CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1 enrolled
Drug / intervention
Lurasidonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03902613
NCT03902613Phase 4Completed
CompareCT.gov

18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder

New York State Psychiatric Institute·interventional·Posted Apr 4, 2019·Updated Nov 13, 2023

In Brief

A Phase 4 clinical trial evaluating Lurasidone for Bipolar Depression. Completed, enrolled 1 participant across 1 site.

Detailed Summary

The goal of this project is to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, the project focuses on the importance of dopamine signaling in the process. Participants will have two different brain scans (MRI and PET scan). They will also have treatment for your depression with an FDA approved medication, lurasidone (Latuda). The study is funded by the Columbia University Irving Institute to improve the treatment of bipolar disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Depression
CountriesUnited States
CollaboratorsColumbia University

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedApr 4, 2019
Enrollment StartFeb 7, 2019
Primary CompletionAug 1, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.2 years ago

Interventions

Lurasidonedrug

Participant will have an open label trial of lurasidone for eight weeks.